XML 29 R36.htm IDEA: XBRL DOCUMENT v3.3.0.814
Debt - Additional Information (Detail)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended
Sep. 30, 2015
USD ($)
May. 31, 2014
USD ($)
shares
d
$ / shares
Jan. 31, 2012
USD ($)
shares
$ / shares
Sep. 30, 2015
USD ($)
Sep. 30, 2014
USD ($)
Sep. 30, 2015
USD ($)
Sep. 30, 2014
USD ($)
Dec. 31, 2014
USD ($)
Dec. 06, 2012
USD ($)
Debt Disclosure [Line Items]                  
Gain on extinguishment of debt             $ 38,034    
Gain (loss) on change in fair value of derivative liability       $ (230) $ 4,466 $ (366) 11,870    
Interest paid           10,225 8,622    
Convertible Debt                  
Debt Disclosure [Line Items]                  
Derivative liability at fair value   $ 3,500              
Gain (loss) on change in fair value of derivative liability           800      
Convertible notes, interest expense           8,500 6,700    
Interest expense, amortization of discount           4,600 2,800    
Interest expense, contractual coupon interest accrual           3,900 3,900    
Accrued interest on convertible note $ 1,100     1,100   1,100   $ 2,400  
Convertible Debt | Finance                  
Debt Disclosure [Line Items]                  
Interest paid           5,300 5,300    
Convertible Debt | 2012 Notes                  
Debt Disclosure [Line Items]                  
Convertible senior notes, principal amount   31,300 $ 150,000            
Convertible senior notes, stated interest rate     3.50%            
Convertible senior notes, due date     2032            
Convertible senior notes, net proceeds     $ 144,300            
Convertible senior notes, payment start date     Jul. 15, 2012            
Convertible senior notes, maturity date     Jan. 15, 2032            
Value of shares in excess of principal amount of Notes based on closing price 24,400     24,400   24,400      
Additional interest rate on notes per annum     0.50%            
Convertible senior notes, repurchase price at option of the issuer     100.00%            
Excess of principal amount of debt over the liability component     $ 23,800            
Convertible senior notes, fair value 27,627     27,627   27,627   25,689  
Note, estimated remaining life     24 months            
Debt discount amortization period     24 months            
Convertible notes, carrying amount net of unamortized discount 31,300     31,300   31,300   31,300  
Decrease to additional paid-in capital for repurchase of conversion option in convertible notes   10,100              
Convertible senior notes, discount 0     0   0   0  
Gain on extinguishment of debt   38,000              
Convertible Debt | 2012 Notes | American Depository Shares                  
Debt Disclosure [Line Items]                  
Convertible senior notes, exchange rate of ADS per $1,000 principal amount of notes     113.4752            
Convertible senior notes, total ADS into which the debt is exchangeable | shares     3,547,916            
Convertible senior notes, initial exchange price | $ / shares     $ 8.8125            
Convertible Debt | 2012 Notes | Exchanged Debt                  
Debt Disclosure [Line Items]                  
Convertible senior notes, principal amount   118,700              
Convertible Debt | 2014 Notes                  
Debt Disclosure [Line Items]                  
Fair value of embedded derivative liability 1,800     1,800   1,800   2,600  
Convertible senior notes, principal amount   $ 118,700              
Convertible senior notes, stated interest rate   3.50%              
Convertible senior notes, due date   2032              
Convertible senior notes, payment start date   Jul. 15, 2014              
Convertible senior notes, maturity date   Jan. 15, 2032              
Value of shares in excess of principal amount of Notes based on closing price 30,600     30,600   30,600      
Convertible senior notes, repurchase price at option of the issuer   100.00%              
Convertible senior notes, fair value 109,608 $ 90,800   109,608   109,608   75,533  
Convertible notes, carrying amount net of unamortized discount 94,800     94,800   94,800   90,600  
Convertible senior notes redemption, end date   Jan. 15, 2032              
Convertible senior notes, mandatory exchange in whole or in part if daily VWAP equals or exceeds percentage of exchange price, in any number of VWAP Trading days | d   30              
Convertible senior notes, discount   $ 27,900              
Underwriter's fees and offering costs   $ 2,500              
Gain (loss) on change in fair value of derivative liability 800                
Convertible Debt | 2014 Notes | American Depository Shares                  
Debt Disclosure [Line Items]                  
Convertible senior notes, exchange rate of ADS per $1,000 principal amount of notes   384.6154              
Convertible senior notes, total ADS into which the debt is exchangeable | shares   45,666,925              
Convertible senior notes, initial exchange price | $ / shares   $ 2.60              
Convertible Debt | 2014 Notes | Minimum                  
Debt Disclosure [Line Items]                  
Convertible senior notes, mandatory exchange in whole or in part if daily VWAP equals or exceeds percentage of exchange price   110.00%              
Convertible senior notes, mandatory exchange in whole or in part if daily VWAP equals or exceeds percentage of exchange price, at least number of VWAP Trading days   20 days              
Convertible Debt | Other debt outstanding | 2012 Notes                  
Debt Disclosure [Line Items]                  
Convertible senior notes, fair value     $ 126,200            
Convertible Debt | Non Cash | 2014 Notes                  
Debt Disclosure [Line Items]                  
Convertible senior notes, discount 23,900     23,900   23,900   $ 28,200  
Biopharma Debt                  
Debt Disclosure [Line Items]                  
Amount received at the closing of the agreement     100,000            
Maximum repayment of future revenue and receivables 139,400     139,400   139,400     $ 150,000
Repayment under agreement       1,800   5,000      
Fair value of embedded derivative liability     $ 14,600            
Gain (Loss) on change in fair value of derivative liability           (300) 6,500    
Biopharma Debt | November 2015                  
Debt Disclosure [Line Items]                  
Future minimum repayment under agreement 2,100     2,100   2,100      
Biopharma Debt | First quarter of 2016                  
Debt Disclosure [Line Items]                  
Future minimum repayment under agreement 10,000     10,000   10,000      
Biopharma Debt | Per quarter in each of the next four quarters                  
Debt Disclosure [Line Items]                  
Future minimum repayment under agreement 15,000     15,000   15,000      
Biopharma Debt | Final Payment in May 2017                  
Debt Disclosure [Line Items]                  
Future minimum repayment under agreement $ 13,000     $ 13,000   13,000      
Biopharma Debt | Cash                  
Debt Disclosure [Line Items]                  
Interest expense           4,900 5,500    
Biopharma Debt | Non Cash                  
Debt Disclosure [Line Items]                  
Interest expense           $ 1,400 $ 1,400